PROMISE

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Aug 30, 2018 → Sep 17, 2026

Cited window

Nov 24, 2018 → May 4, 2026

Retrieved

Nov 1, 2026

Title

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

Registry

NCT03689595

Study IDs

18-370

Sponsor

Dana-Farber Cancer Institute

Design

Observational · Observational, cohort, prospective

Status

Enrolling by invitation

Enrollment

30,000 estimated

Registered

2018-09-28

Start

2018-10-31 actual

Primary completion

2033-10-31 estimated

Primary endpoint

Time to progression (TTP) from MGUS/SMM to overt multiple myeloma.

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –79 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits apply, so some matching discussion may be missing.
• –The sources reviewed for this edition are not a representative sample of HCP opinion. Searches emphasized PROMISE and its identifiers, and 849 potentially relevant sources that did not name the trial were not read; indirect discussion may therefore be missing.
• –Several available passages were not fully evaluated. A further passage had unclear disease-population wording and could not support a reliable conclusion. The report cannot establish that all consequential views or objections have been captured.
• –The HealthTree video passages are unattributed. They cannot be assigned to a named clinician or counted as additional independently identified endorsements.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –A speaker’s PROMISE role and another speaker’s Dana-Farber association are descriptions made by the sources. Their views should not be treated as independent external endorsements or evidence of consensus.
• –Eligibility, screening counts, follow-up procedures and assay availability are described at different times. The sources do not establish current eligibility, reconcile recruitment figures or demonstrate present-day access across healthcare settings.
• –No standalone protocol was available. The free-light-chain publication was accessible only as an abstract, limiting assessment of its full methods and qualifications.
• –Prevalence findings, biobank clinical associations, progression hypotheses and hoped-for prevention benefits are different forms of evidence. The statements reviewed do not demonstrate a mortality, organ-damage prevention or cure benefit from PROMISE screening.

How reports are built and checked: Methods.

Last checked for new commentary Nov 2, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "PROMISE" (NCT03689595), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "promise-03689595". If you cannot make requests, read https://www.erudio.com/reports/promise-nct03689595.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT03689595", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct03689595 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/promise-nct03689595.json
curl https://www.erudio.com/reports/promise-nct03689595.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "promise-03689595" })